Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2020.12.005 http://scihub22266oqcxt.onion/10.1016/j.drudis.2020.12.005 33309533!7724992!33309533     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\33309533.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Drug+Discov+Today 2021 ; 26 (3): 804-816 Nephropedia Template TP {{tp|p=33309533|t=2021. Potential SARS-CoV-2 main protease inhibitors |pdf=|usr=}}{{33309533}} gab.com Text Potential SARS-CoV-2 main protease inhibitors JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=33309533 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic has prompted an urgent need for new treatment strategies. No target-specific drugs are currently available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but new drug candidates targeting the viral replication cycle are being explored. A prime target of drug-discovery efforts is the SARS-CoV-2 main protease (M(pro)). The main proteases of different coronaviruses, including SARS-CoV-2, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), share a structurally conserved substrate-binding region that can be exploited to design new protease inhibitors. With the recent reporting of the X-ray crystal structure of the SARS-CoV-2 M(pro), studies to discover M(pro) inhibitors using both virtual and in vitro screening are progressing rapidly. This review focusses on the recent developments in the search for small-molecule inhibitors targeting the SARS-CoV-2 M(pro). Twit Text FOAVip Potential SARS-CoV-2 main protease inhibitors ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=33309533 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33309533 #FOAvip English Wikipedia <ref>{{Cite pmid|33309533}}</ref> Potential SARS-CoV-2 main protease inhibitors #MMPMID33309533 Banerjee R; Perera L; Tillekeratne LMV Drug Discov Today 2021[Mar]; 26 (3): 804-816 PMID33309533show ga The coronavirus disease 2019 (COVID-19) pandemic has prompted an urgent need for new treatment strategies. No target-specific drugs are currently available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but new drug candidates targeting the viral replication cycle are being explored. A prime target of drug-discovery efforts is the SARS-CoV-2 main protease (M(pro)). The main proteases of different coronaviruses, including SARS-CoV-2, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), share a structurally conserved substrate-binding region that can be exploited to design new protease inhibitors. With the recent reporting of the X-ray crystal structure of the SARS-CoV-2 M(pro), studies to discover M(pro) inhibitors using both virtual and in vitro screening are progressing rapidly. This review focusses on the recent developments in the search for small-molecule inhibitors targeting the SARS-CoV-2 M(pro). |*COVID-19 Drug Treatment[MESH] |*Coronavirus 3C Proteases/antagonists & inhibitors/chemistry/metabolism[MESH] |*SARS-CoV-2/drug effects/physiology[MESH] |Drug Design[MESH] |Drug Discovery/*methods[MESH] |Humans[MESH]Potential SARS-CoV-2 main protease inhibitors (epmc).pdf DeepDyve Pubget Overpricing